Mar 16, 2022 / 06:05PM GMT
Luke England Sergott - Evercore ISI Institutional Equities, Research Division - Former Associate
Good afternoon, everybody. My name is Luke Sergott. I cover life sciences tools and diagnostics at Barclays. It's my pleasure to introduce Bob McMahon from Agilent. We're just going to kind of dive in here, but if you want to give a couple of points and then we can go into the questions.
Robert W. McMahon - Agilent Technologies, Inc. - Senior VP & CFO
Yes, sure. So it's great to see people in person after a long respite. So -- but -- the good news is Agilent continues to have a very strong business. And we just finished our first quarter with strong double-digit growth. And actually, our orders grew faster than our revenues. And so we see continued business momentum and are excited about our prospects going forward. I'm sure we'll talk about some of the growth drivers that we have as we continue to transition our business to more of those faster-growing areas. And so let's jump right in.
Agilent Technologies Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers